Introduction
Tumor suppressor p53, also known as the guardian of the genome, is a transcription factor essential for tumor suppression in mammals. While p53 remains in an inert and unstable state in normal cells in the absence of stresses, its activity and stability are significantly induced after most genotoxic and cellular stresses (Ko and Prives, 1996) . As a transcription factor, p53 directly binds to the promoters of many checkpoint and apoptotic genes, including Puma, p21, Mdm-2, GADD45, Perp, Noxa and cyclin G, and activates their transcription (Gudkov, 2003; Wei et al., 2006) . In addition, p53 can directly suppress the expression of numerous genes, including Nanog, MAP4 and Survivin (Murphy, 2003; Lin et al., 2005) . The activation of p53 leads to cell cycle arrest, senescence, apoptosis or differentiation, partly depending on the cell type and intensity of the stresses (Campisi, 2005; Xu, 2005; Yee and Vousden, 2005) . These roles of p53 could all make contributions to preventing the accumulation and passage of DNA damage to the daughter cells.
It has become evident that the transcriptional activity of p53 is critical for its functions. p21 and 14-3-3s, both transcriptional targets of p53, are required for mediating p53-dependent cell cycle G 1 /S and G 2 /M cell cycle checkpoints Brugarolas et al., 1995; Deng et al., 1995; Hermeking et al., 1997) . Several lines of evidence also indicate that transcription activity of p53 is required for p53-dependent apoptosis after DNA damage. In this context, both p53-dependent transcription and apoptosis are abolished in p53 Gln25Ser26 knock-in cells after DNA damage (Chao et al., 2000; Johnson et al., 2005) . In addition, Puma, a transcriptional target of p53 (Nakano and Vousden, 2001; Yu et al., 2001) , is required for p53-dependent apoptosis after DNA damage (Jeffers et al., 2003; Villunger et al., 2003) .
Recent evidence also reveals the transcription-dependent roles of p53 in the cellular differentiation. For example, p53 induces the differentiation of embryonic stem (ES) cells by directly suppressing the expression of Nanog, which is required for the self-renewal of ES cells . In addition, p53 also suppresses the self-renewal of the neural stem cells in a transcriptiondependent manner (Meletis et al., 2006) . It is well established that p53 is required for the replicative senescence. The requirement of the transcriptional activity of p53 in senescence has been supported by recent findings that p53 target gene Plasminogen activator inhibitor-1 is required for p53-dependent replicative senescence (Kortlever et al., 2006 (Kortlever et al., ). 1995 . Therefore, p53-dependent cell cycle arrest alone might not be critical for p53-dependent suppression of tumorigenesis and polyploidy. Puma-deficient mice are essentially defective in p53-dependent apoptosis but are not cancer prone, indicating that apoptosis alone might not be critical for p53-dependent tumor suppression (Jeffers et al., 2003; Villunger et al., 2003) . The synergistic roles of p53-dependent cell cycle arrest and apoptosis in tumor suppression have been supported by the findings that disruption of both p53-dependent apoptosis and cell cycle arrest but not senescence leads to greatly increased spontaneous tumorigenesis in mice (Chao et al., 2003 (Chao et al., , 2006 .
While the involvement of p53-dependent senescence and differentiation in tumor suppression is less well studied, recent studies support an important role of p53-dependent senescence in suppressing oncogene-induced tumorigenesis (Braig et al., 2005; Chen et al., 2005) . Indirect evidence also implicates the potential roles of p53-dependent differentiation in tumor suppression. For example, the p53-induced differentiation of ES cells and neural stem cells after DNA damage suggests the involvement of p53 in maintaining genetic stability in stem cell pools (Xu, 2005; Meletis et al., 2006) . This could suppress the generation of cancer stem cells, which are usually the transformed descendants of normal adult stem cells.
p53 cancer mutations
The inactivation of p53-dependent tumor suppression is required for the progression of most human cancers. p53 can be inactivated in human cancers either by the somatic gene mutation or by the disruption of pathways that are important for p53 activation. Most of these p53 gene mutations, which are detected in over half of all human cancers, are missense mutations within the DNA-binding core domain (Hainaut and Hollstein, 2000) . Four hot spot mutations at residue Arg175, 248, 249 and 273 together account for over 25% of all missense mutations identified in human cancers (Hainaut and Hollstein, 2000) . Based on the impact of the mutation on the structure and function of p53, p53 cancer mutations can be generally divided into two categories: contact mutation and structure mutation (Joerger and Fersht, 2007) . Both R248W and R273H mutations are classified as DNA contact mutations, which will directly disrupt the binding of p53 to its target promoters, leading to the loss of the tumor suppression activity of p53. In addition, these contact mutations also induce subtle conformational change of the core domain (Joerger and Fersht, 2007) . R175H and R249S mutations are classified as structural mutations that induce substantial conformational change or the denaturation of the core domain, leading to the loss of p53-dependent tumor suppression. p53 cancer mutants partially or completely lose the wild-type p53-dependent tumor suppression activities. In this context, studies in cancer cell lines have shown that the common p53 cancer mutants cannot bind to p53 target promoters and transactivate target gene expression (el-Deiry et al., 1992; Farmer et al., 1992; Kern et al., 1992; Scharer and Iggo, 1992) . In addition, recent studies in the p53 cancer mutation knock-in mice also indicate that the common p53 cancer mutations abolish the wild-type p53-dependent tumor suppression activities in vivo (Lang et al., 2004; Olive et al., 2004; Song et al., 2007) .
Gain-of-function of p53 cancer mutants In addition to the loss of tumor suppression activity, accumulating evidence also indicates that p53 cancer mutants gain new oncogenic activities in promoting tumorigenesis and drug resistance. For example, p53 mutants can collaborate with the oncogenic Ras protein to transform primary rat cells in vitro and enhance Rasinduced tumorigenesis in immunodeficient mice (Finlay et al., 1989; Hinds et al., 1990; Dittmer et al., 1993; Slingerland et al., 1993; Preuss et al., 2000) . In addition, p53 cancer mutants can promote the resistance of cancer cells to p53-independent apoptosis induced by cytotoxic drugs (Li et al., 1998) . These gain-of-functions of p53 cancer mutants could account for the close correlation between the expression of p53 mutants and the poor prognosis of cancer patients. For example, expression of p53 mutants but not the p53-deficiency is correlated with the poor prognosis in soft tissue sarcomas (Taubert et al., 1996) . In addition, R175H mutation is correlated with the poor prognosis of small-cell lung carcinomas (Vega et al., 1997) .
Genetic instability is a key stimulus of tumorigenesis
Genetic instability is a universal characteristic of human cancers and allows the efficient accumulation of genetic mutations to promote growth, survival and drug resistance of cancer cells (Goldie, 2001 ). There are several types of genetic instability commonly associated with human cancers, including aneuploidy, microsatellite instability and chromosomal translocation. Aneuploidy, which refers to the abnormal chromosome content, is commonly associated with many types of tumors (Kops et al., 2005) . Aneuploidy is usually caused by the defective mitotic checkpoint as a result of the mutation in tumor suppressor genes, such as p53, RB, APC and BRCA1. Microsatellite refers to the repetitive sequence present abundantly in the mammalian genome. Microsatellite instability as a result of the deficiency in DNA mismatch repair pathways plays an important role in promoting tumorigenesis in colorectal, endometrial and certain other cancers (Woerner et al., 2006) . Chromosomal translocation has long been known as a common cause of human leukemia, lymphomas and sarcomas by deregulating the expression of oncogenes or disrupting the tumor suppressor gene (Zhang and Rowley, 2006) . The recent development of more sophisticated assays such as spectrum karyotyping in the analysis of genetic instability has indicated that chromosomal translocation is also common in solid tumors (Mitelman et al., 2007) . This type of genetic instability is usually caused by the defects in nonhomologous end joining machinery required for the repair of DNA double-stranded break (DSB) damage as well as defects in ATM-dependent cellular responses to DNA DSB damage (Franco et al., 2006; Xu, 2006) . ATM-dependent pathways in suppressing chromosomal translocation ATM is a protein kinase mutated in the genetic instability syndrome ataxia-telangiectasia (A-T) characterized by multisystemic defects, including cerebellar degeneration (ataxia), facial telangiectasia, germ cell defects, immunodeficiency, high cancer risk and radiosensitivity (Savitsky et al., 1995) . Chromosomal translocation is common in A-T cells, indicating that ATM is required to suppress this type of genetic instability (Shiloh and Kastan, 2001) . ATM is the master regulator to activate cellular responses to DNA DSB damage, including the activation of cell cycle checkpoints at G 1 /S, S and G 2 /M (Shiloh, 2003) . In addition, ATM might also play a role in activating the repair of DNA DSB damage (Riballo et al., 2004) . Two other ATMrelated mammalian kinases, ATM-related (ATR) and DNA-protein kinase (PK) catalytic subunit, are involved in cellular responses to single-stranded DNA damage and nonhomologous end joining of DSBs, respectively (Xu, 2006) .
Activation of ATM after DNA DSB damage
While ATM is activated shortly after the introduction of DNA DSB damage, it is not involved in the initial sensing of DNA damage (Figure 1 ). Recent studies have indicated that the Mre11/Rad50/NBS1 (MRN) complex is important in the initial sensing of DNA DSB damage and activation of ATM (Carson et al., 2003; Uziel et al., 2003) . In this context, structural and functional studies have shown that MRN complex directly binds to DNA DSBs (Hopfner et al., 2001; Hopfner et al., 2002) . Once MRN complex binds to the site of DNA damage, it could recruit ATM to DNA DSBs through the direct interaction between ATM and NBS1 (Falck et al., 2005; Lee and Paull, 2005; You et al., 2005) . In support of this notion, ATM activation, which is marked by the autophosphorylation of ATM at Ser1981 (Bakkenist and Kastan, 2003) , is impaired in the NBS1-deficient human cells (Carson et al., 2003; Uziel et al., 2003) . The recruitment of ATM to the site of DNA damage is also impaired in NBS1 mutant cells (Kitagawa et al., 2004; Difilippantonio et al., 2005) . In addition, recent genetic studies have shown that hypomorphic mutation in NBS1 and Mre11 leads to A-T-related systemic and cellular defects in mice (Kang et al., 2002; Theunissen et al., 2003; Difilippantonio et al., 2005; Kang et al., 2005) . Once activated ATM is recruited to the site of DNA damage, it phosphorylates and activates a panel of DNA repair and cell cycle checkpoint proteins that are also recruited to the site of DNA damage (Xu, 2006) . The phosphorylation of the ATM substrates, including p53, H2AX, NBS1, 53BP1, BRCA1, SMC1, NBS1, Chk2 and Rad17, activates all three cell cycle checkpoints at G 1 /S, S and G 2 /M as well as efficient DNA repair (Shiloh, 2003) .
Gain-of-function of p53 cancer mutants in inducing genetic instability
The mechanisms underlying the gain-of-function of p53 cancer mutants could be both transcription dependent and transcription independent. Since there is no strong evidence that various p53 cancer mutants can bind to Induction of genetic instability Y Xu specific DNA sequences, p53 mutants likely modulate gene transcription through the association with other transcriptional factors or competition for the coactivators (Strano et al., 2007; Weisz et al., 2007) . Protein-protein interaction between p53 mutants and other cellular proteins also appears to be a common mechanism underlying the transcription-independent gain-of-function of p53 cancer mutants, leading to the disruption of the normal activities of these cellular proteins. For example, some p53 cancer mutants can interact with topoisomerase I and stimulate its activity, leading to increased genomic recombination in cancer cells (Albor et al., 1998) . In addition, the interaction between some p53 mutants and p53 family members p73 inhibits the p73-dependent apoptosis after DNA damage (Li and Prives, 2007) .
Mouse models to study p53 cancer mutants Mouse models have become powerful genetic tools to investigate the gain-of-function of p53 cancer mutants. Two hot spot p53 cancer mutations (R175H and R273H) have been introduced into the corresponding codons of the endogenous p53 gene in mice through homologous recombination and LoxP/Cre-mediated deletion (Lang et al., 2004; Olive et al., 2004) . As expected, these knockin mutations (R172H and R270H) abolish the wild-type p53-dependent gene expression and functions (Lang et al., 2004; Olive et al., 2004) . When compared with p53 À/À mice, the mutant mice develop distinct spectrum of tumors, supporting a gain-of-function of p53 cancer mutants in tumorigenesis in mice. In addition, similarly to the findings in human cancer cells, R172H mutant can interact with other p53 family members p73 and p63 to inhibit their activities in the knock-in mouse cells (Gaiddon et al., 2001; Strano et al., 2002; Lang et al., 2004) . Since p73 can induce p53-independent apoptosis after DNA damage (Stiewe, 2007) and play synergistic roles with p53 in tumor suppression (Flores et al., 2005) , these findings identify a gain-of-function of certain p53 mutants in promoting tumorigenesis through the interaction with p73.
The development of the humanized p53 knock-in (HUPKI) mouse model provides the opportunity to better model the p53 cancer mutants in mice. HUPKI, which is composed mostly of the human sequence (amino-acid residues 33-332) together with the extreme N-and C termini of the mouse p53, is functionally identical to complete mouse p53 in tumor suppression in mice (Luo et al., 2001; Feng et al., 2006) . Because the core domains of the mouse and human p53 are only 75% identical, it has been reasoned that the impact of the hot spot mutations on the structure and function of human p53 could be more faithfully recapitulated by introducing the mutation into the HUPKI allele than into the corresponding residues of the endogenous mouse p53 allele (Hergenhahn et al., 2004) .
Chronic activation of DNA damage responses in the stabilization of p53 mutants To elucidate the gain-of-function of p53 cancer mutants in promoting tumorigenesis, the most common p53 cancer mutations (R248W and R273H) were independently introduced into the HUPKI allele in mice, denoted p53hmki mice (Song et al., 2007) . Consistent with the previous report of R172H knock-in mice (Lang et al., 2004; Olive et al., 2004) , the mutant p53 protein is accumulated in the cultured p53hmki mouse embryonic fibroblasts (MEFs) but not in other primary cells such as thymocytes (Song et al., 2007) . Mdm2, a transcription target of p53, binds to the N terminus of p53 and functions as an E3 ligase of p53, leading to the ubiquitination and degradation of p53. However, the stabilization of the mutant p53 in p53hmki MEFs is not due to the lack of Mdm2 (Song et al., 2007) . Instead, this is due to the constitutive phosphorylation of the N terminus of p53 mutants that disrupts the interaction between p53 mutants and Mdm2 (Song et al., 2007) . The constitutive phosphorylation of p53 supports the notion that the DNA damage response pathways are chronically active in p53hmki MEFs. Since p53 is important for the cellular responses to oxidative stresses that can induce DNA damage (Ben-Porath and Weinberg, 2005) , it is possible that the accumulation of the endogenous DNA damage in p53hmki MEFs cultured under oxidative condition leads to the constitutive activation of DNA damage pathways in these cells. The DNA damage responses are also chronically activated in human cancer cells (Bartkova et al., 2005; Gorgoulis et al., 2005) . Therefore, the same mechanism could account for the stabilization of p53 mutants in the human cancer cells. Since tumor cells are constantly under pressure for growth and survival advantages in vivo, these findings also support the notion that the stabilization of p53 cancer mutants is selected for during tumorigenesis.
Functional inactivation of ATM by p53 cancer mutants
Polyploidy is the type of genetic instability associated with p53-deficiency in mouse and human cells (Kops et al., 2005) . However, other type of genetic instability such as chromosomal translocation is rarely found in p53-deficient cells (Bassing et al., 2003; Celeste et al., 2003; Song et al., 2007) . Interestingly, the analysis of p53hmki thymocytes shows greatly increased frequency of inter-chromosomal translocation (Song et al., 2007) . In addition, Ionizing radiation (IR)-induced G 2 /M checkpoint is inactivated by the p53 cancer mutants in both primary and tumor cells derived from p53hmki mice (Song et al., 2007) . Because chromosomal translocation and defective G 2 /M checkpoint are commonly found in all types of human cancers (Mitelman et al., 2007) , this gain-of-function of p53 cancer mutants might represent a major mechanism by which p53 cancer mutants promote oncogenesis.
Impaired activation of ATM by p53 mutants ATM is critical to suppress chromosomal translocation and activate G 2 /M checkpoint after DNA DSB damage (Shiloh, 2003) . While the phosphorylation of ATM at Ser1981, a marker for ATM activation, is normal in p53hmki cells after DNA DSB damage, the recruitment Induction of genetic instability Y Xu of activated ATM to the site of DNA damage is impaired in the p53hmki cells due to the disrupted recruitment of Mre11 complex to the site of DNA damage (Figure 2 ; Song et al., 2007) . Because the recruitment of ATM to the site of DNA damage is important for the ATM-dependent phosphorylation of its substrates, the impaired recruitment of ATM to the site of DNA damage inactivates its function. In support of this notion, the ATM-dependent phosphorylation of H2AX, NBS1 and SMC1 is defective in p53hmki cells after DNA DSB damage. Importantly, this gain-offunction of p53 cancer mutants in inactivating ATM is also evident in human cancer cells expressing the common p53 cancer mutants (Song et al., 2007) . There are two potential ways for p53 mutants to interrupt the recruitment of MRN complex to the site of DNA damage. First, p53 mutants directly bind to DNA DSBs and compete with MRN complex to bind to the site of DNA damage. Second, p53 mutants might interact with MRN complex to prevent the binding of MRN complex to the site of DNA damage. The second possibility is supported by the findings that the common p53 cancer mutants (R248W and R273H) physically interact with Mre11 in both p53 mutant knock-in mouse cells and human cancer cells expressing these p53 mutants (Song et al., 2007) . These findings reveal a novel mechanism for p53 cancer mutants to induce genetic instability by disrupting critical DNA damage responses to DSBs, which occur physiologically during cellular proliferation (Figure 2 ). Since MRN complex and ATM are rarely mutated in human cancers, this gain-of-function of p53 cancer mutants could also account for the high frequency of chromosomal translocations in various types of human cancers. p53 cancer mutants suppress apoptosis after DNA damage While ATM-defective cells and mice are radiosensitive (Barlow et al., 1996; Shiloh and Kastan, 2001) , the human cancer cells expressing p53 cancer mutants are not radiosensitive despite the impaired ATM function. This is likely due to the gain-of-function of p53 mutants in suppressing multiple apoptotic pathways (Figure 2) . First, the loss of wild-type p53-dependent apoptosis in human cancer cells that express p53 mutants will confer radioresistance to some cell types. In support of this notion, identical to p53 À/À thymocytes, Atm
À/À thymocytes are resistant to p53-dependent apoptosis after IR (Xu et al., 1998) . Second, some p53 cancer mutants can suppress the function of p73 that induces p53-independent apoptosis after DNA damage (Li and Prives, 2007) . This gain-of-function could also lead to resistance to apoptosis induced by DNA damage agents in certain cell types. Third, the transcription-dependent gain-of-function of p53 mutants causes the downregulation of pro-apoptotic genes and upregulation of pro-survival genes, leading to resistance to apoptosis induced by DNA damage (Weisz et al., 2007) . For example, p53 mutants can induce the expression of BAG-1, an antiapoptotic factor and suppresses the expression of FAS and MST-1 gene, leading to resistance to apoptosis (Zalcenstein et al., 2003 (Zalcenstein et al., , 2006 . In summary, the simultaneous gain-of-functions of p53 cancer mutants in inactivating ATM and suppressing apoptosis provide a mechanism by which p53 cancer mutants effectively induce chromosomal translocations in human cancer cells (Figure 2 ).
Implications on cancer therapy
The gain-of-function of p53 cancer mutants promotes drug resistance and oncogenesis, contributing to the poor prognosis of the cancer patients. Considering the important roles of genetic instability such as chromosomal translocation in promoting tumorigenesis, the gain-of-function of p53 cancer mutants in inactivating ATM could make significant contribution to drug resistance and cancer progression. In this context, many current cancer treatments such as radiotherapy kills cancer cells by inducing DNA DSB damage in their genome, and thus require functional ATMdependent pathways to suppress the growth and survival of the cancer cells. The excessive DNA DSB damage induced by certain cancer treatments together with the defective ATM function in human cancer cells expressing p53 mutants could unintentionally induce chromosomal translocations, promoting the genetic mutation and metastatic potential of the surviving cancer cells. Therefore, it might be clinically beneficial to develop a strategy to restore ATM function in human cancer cells expressing p53 mutants by disrupting the interaction between p53 mutants and Mre11. In addition, based on the findings that a co-expressed 
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wild-type p53 can suppress the accumulation of some common p53 cancer mutants by inhibiting the accumulation of endogenous DNA damage, gene therapy with wild-type p53 might be effective to treat human cancers expressing these common p53 cancer mutants.
